<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/immunitybio-inc-ibrx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302769929.html">ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        LOS ANGELES, May 12, 2026 /PRNewswire/ -- Glancy Prongay Wolke &amp; Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. (&quot;ImmunityBio&quot; or the &quot;Company&quot;) (NASDAQ: IBRX). IF YOU SUFFERED A LOSS ON YOUR IMMUNITYBIO INVESTMENTS, CLICK  HERE BEFORE MAY 26, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURI...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/ibrx-shareholder-update-immunitybio-ibrx-sued-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost----hagens-berman-302768350.html">IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, May 11, 2026 /PRNewswire / -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scient...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/ibrx-investors-have-opportunity-to-lead-immunitybio-inc-securities-fraud-lawsuit-first-filed-by-the-rosen-law-firm-302767303.html">IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the &quot;Class Period&quot;), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityBi...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/immunitybio-inc-ibrx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302767279.html">ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        BENSALEM, Pa., May 8, 2026 /PRNewswire/ -- The Law Offices of Howard G.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/08/3291235/32716/en/IBRX-Lawsuit-Alleges-Company-Allegedly-Violated-Drug-Promotion-Laws-ImmunityBio-Investors-Face-Losses-Following-Company-Allegedly-Violated-Drug-Promotion-Laws-Hagens-Berman.html">IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, May 08, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260507366251/en/ImmunityBio-Reports-Record-Q1-2026-Results-Net-Product-Revenue-Increased-Nearly-2.7x-Year-Over-Year-to-44-Million-in-Q1-2026-Expanding-on-the-2025-Full-Year-700-Year-Over-Year-Revenue-Growth-Cash-and-Marketable-Securities-Total-381-Million/">ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million</a>
    </div>

      <div class="me-0 me-md-5">
        CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company reported net product revenue of approximately $44.2 million during the three months ended March 31, 2026, with net product revenue growth in every quarter since ANKTIVA&#39;s commercial launch, includ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/06/3289529/0/en/IMMUNITYBIO-CLASS-ACTION-ALERT-Bragar-Eagel-Squire-P-C-Encourages-Immunity-Bio-Inc-Stockholders-with-Significant-Losses-to-Contact-the-Firm-Regarding-Their-Rights.html">IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel &amp; Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights</a>
    </div>

      <div class="me-0 me-md-5">
        Bragar Eagel &amp; Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/ImmunityBio-Inc-US45256X1037">ImmunityBio Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/06/3289474/32716/en/IBRX-Lawsuit-Alleges-Company-Allegedly-Violated-Drug-Promotion-Laws-ImmunityBio-Investors-Face-Losses-Following-Company-Allegedly-Violated-Drug-Promotion-Laws-Hagens-Berman.html">IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, May 06, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Sci...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/ImmunityBio-Inc-US45256X1037/load_more?page=6">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>